At a glance
ClinicalIndex Comparison RecordN/ACompleted· 243 enrolled
Drug / intervention
Temsirolimus (Non-Interventional Study)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhibitor - Estudio Retrospectivo De Casos Clinicos De Pacientes Con Carcinoma De Celulas Renales Y Con Linforma De Celulas Del Manto Tratados Con Temsirolimus
In Brief
An observational study evaluating Temsirolimus (Non-Interventional Study) for Carcinoma, Renal Cell and Lymphoma, Mantle-Cell. Completed, enrolled 243 participants across 16 sites.
Detailed Summary
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell, Lymphoma, Mantle-Cell
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJun 2011
Primary CompletionApr 2015
TodayJul 2026
First PostedJun 7, 2011
Enrollment StartJan 1, 2011
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.1 years ago
Interventions
Temsirolimus (Non-Interventional Study)other
There is not any intervention in this study.